Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo
- 890 Downloads
Amisulpride is approved for clinical use in treating schizophrenia in a number of European countries and also for treating dysthymia, a mild form of depression, in Italy. Amisulpride has also been demonstrated to be an antidepressant for patients with major depression in many clinical trials. In part because of the selective D2/D3 receptor antagonist properties of amisulpride, it has long been widely assumed that dopaminergic modulation is the proximal event responsible for mediating its antidepressant and antipsychotic properties.
The purpose of these studies was to determine if amisulpride’s antidepressant actions are mediated by off-target interactions with other receptors.
Materials and Methods
We performed experiments that: (1) examined the pharmacological profile of amisulpride at a large number of central nervous system (CNS) molecular targets and, (2) after finding high potency antagonist affinity for human 5-HT7a serotonin receptors, characterized the actions of amisulpride as an antidepressant in wild-type and 5-HT7 receptor knockout mice.
We discovered that amisulpride was a potent competitive antagonist at 5-HT7a receptors and that interactions with no other molecular target investigated in this paper could explain its antidepressant actions in vivo. Significantly, and in contrast to their wild-type littermates, 5-HT7 receptor knockout mice did not respond to amisulpride in two widely used rodent models of depression, the tail suspension test and the forced swim test.
These results indicate that 5-HT7a receptor antagonism, and not D2/D3 receptor antagonism, likely underlies the antidepressant actions of amisulpride.
KeywordsAmisulpride 5-HT7 5-HT7 antagonist Antidepressant Atypical antipsychotic DAN 2163
A.A., X.P.H., T.B.T., and B.L.R. were supported by NIMH61887, U19MH82441, and the NIMH Psychoactive Drug Screening Program; B.L.R. received additional support as a NARSAD Distinguished Investigator. A.A. was also supported by the CWRU MSTP and NIH T32 GM007250. P.B.H. was supported by NIMH MH73923.
- Brunello N, Armitage R, Feinberg I, Holsboer-Trachsler E, Leger D, Linkowski P, Mendelson WB, Racagni G, Saletu B, Sharpley AL, Turek F, Van Cauter E, Mendlewicz J (2000) Depression and sleep disorders: clinical relevance, economic burden and pharmacological treatment. Neuropsychobiology 42:107–119PubMedCrossRefGoogle Scholar
- Gibbs A, Naudts K, Spencer E, David A (2008) Effects of amisulpride on emotional memory using a dual-process model in healthy male volunteers. J Psychopharmacol 22:1–9Google Scholar
- Guscott M, Bristow LJ, Hadingham K, Rosahl TW, Beer MS, Stanton JA, Bromidge F, Owens AP, Huscroft I, Myers J, Rupniak NM, Patel S, Whiting PJ, Hutson PH, Fone KC, Biello SM, Kulagowski JJ, McAllister G (2005) Genetic knockout and pharmacological blockade studies of the 5-HT7 receptor suggest therapeutic potential in depression. Neuropharmacology 48:492–502PubMedCrossRefGoogle Scholar
- Kim SW, Shin IS, Kim JM, Lee SH, Lee JH, Yoon BH, Yang SJ, Hwang MY, Yoon JS (2007) Amisulpride versus risperidone in the treatment of depression in patients with schizophrenia: a randomized, open-label, controlled trial. Prog Neuropsychopharmacol Biol Psychiatry 31:1504–1509PubMedCrossRefGoogle Scholar
- Kvachnina E, Liu G, Dityatev A, Renner U, Dumuis A, Richter DW, Dityateva G, Schachner M, Voyno-Yasenetskaya TA, Ponimaskin EG (2005) 5-HT7 receptor is coupled to G alpha subunits of heterotrimeric G12-protein to regulate gene transcription and neuronal morphology. J Neurosci 25:7821–7830PubMedCrossRefGoogle Scholar
- Motulsky H, Christopoulos A (2004) Fitting models to biological data using linear and nonlinear regression: a practical guide to curve fitting. Oxford University Press, OxfordGoogle Scholar
- Schoemaker H, Claustre Y, Fage D, Rouquier L, Chergui K, Curet O, Oblin A, Gonon F, Carter C, Benavides J, Scatton B (1997) Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther 280:83–97PubMedGoogle Scholar
- Thomas DR, Melotto S, Massagrande M, Gribble AD, Jeffrey P, Stevens AJ, Deeks NJ, Eddershaw PJ, Fenwick SH, Riley G, Stean T, Scott CM, Hill MJ, Middlemiss DN, Hagan JJ, Price GW, Forbes IT (2003) SB-656104-A, a novel selective 5-HT7 receptor antagonist, modulates REM sleep in rats. Br J Pharmacol 139:705–714PubMedCrossRefGoogle Scholar
- Wetzel H, Grunder G, Hillert A, Philipp M, Gattaz WF, Sauer H, Adler G, Schroder J, Rein W, Benkert O (1998) Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology—a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-/D2-like antagonist. The Amisulpride Study Group. Psychopharmacology (Berl) 137:223–232CrossRefGoogle Scholar